Bubbles Save the Day: Scientists Cure Rare Genetic Disease with Custom Molecule

Breakthrough in Gene Therapy for Alpha-1 Antitrypsin Deficiency

A groundbreaking study has demonstrated the potential of using tiny fat bubbles to deliver gene therapy and repair DNA in animals suffering from alpha-1 antitrypsin deficiency. This development marks a significant step forward in the treatment of this rare genetic disorder, which affects both the lungs and liver.

The research, published in Nature Biotechnology, was conducted by scientists at UT Southwestern Medical Center. They used lipid nanoparticles—hollow, fatty spheres that are 100,000 times smaller than the thickness of a piece of paper—to target and enter lung and liver cells. These particles have a natural tendency to accumulate in the liver, making them ideal for treating liver-related conditions. However, the study showed that by modifying the composition of these nanoparticles, they could also reach the lungs effectively.

In mice with a genetic mutation causing alpha-1 antitrypsin deficiency, the targeted lipid nanoparticles delivered a gene therapy payload that corrected about 40% of affected liver cells and 10% of lung cells. This led to a reduction of over 80% in the levels of an abnormal protein associated with the condition. Dr. Terence Flotte, a pediatric pulmonologist not involved in the study, praised the results, calling them “pretty darn convincing.”

Understanding Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency is a genetic disorder that can damage the lungs, liver, or both. It affects approximately 80,000 to 100,000 people in the U.S., all due to mutations in the SERPINA1 gene. This gene normally produces alpha-1 antitrypsin, a protein that protects the lungs from an enzyme called neutrophil elastase. When the protein is missing or misshapen due to a mutation, it clumps up in the liver instead of reaching the lungs, leading to severe damage.

Current treatments such as augmentation therapy, which involves using plasma from healthy donors to raise protein levels, can help ease symptoms but do not offer a cure. Scientists are now turning to gene therapy as a promising alternative.

The Role of Lipid Nanoparticles

Lipid nanoparticles have become a key tool in modern medicine, capable of delivering various types of cargo, including vaccines, chemotherapy drugs, and antibiotics. However, one major challenge in gene therapy is directing these particles to the right cells in the body.

The liver, which processes fats, often intercepts these particles, making it difficult to target other organs. Daniel Siegwart, a professor of biomedical engineering at UT Southwestern, has spent over a decade working on solving this problem. His research focused on creating lipid nanoparticles that could selectively target specific organs rather than just the liver.

A New Approach to Targeting Organs

Lipid nanoparticles have molecular components on their surface that bind to matching structures on cells, much like a key fitting into a lock. By altering these molecular parts, Siegwart and his team developed a recipe for nanoparticles that could target specific organs. Their formula included four lipids: an ionizable aminolipid, cholesterol, a phospholipid, and a polyethylene glycol-lipid. Adding a fifth lipid, named DORI, allowed the particles to bypass the liver and target the lungs instead.

To test this approach, the researchers loaded the nanoparticles with a base editor that corrected a variant of the mutated SERPINA1 gene. In mice with alpha-1 antitrypsin deficiency, the treatment led to significant improvements, with 40% of liver cells and 10% of lung cells being corrected. The results were so promising that the researchers observed an 80% restoration of normal liver function and 90% restoration in the lungs.

Future Directions and Implications

This breakthrough comes at a time when other companies are also exploring gene therapy for alpha-1 antitrypsin deficiency. Beam Therapeutics, based in Boston, recently announced initial data from an early-stage clinical trial for its gene therapy, BEAM-302, which targets the SERPINA1 gene in the liver.

While this approach may address both liver and lung issues, more research is needed to determine how long the effects last and whether this method works in other animal models. For example, ferrets with the same condition could be used to conduct tests similar to those done in humans.

Siegwart and his team are looking to expand their research to other genetic diseases, including cystic fibrosis and primary ciliary dyskinesia. ReCode Therapeutics, a company he co-founded, is already studying these lipid nanoparticles as delivery vehicles for gene therapies targeting these conditions. In March, the company received Orphan Drug Designation from the FDA for an investigational cystic fibrosis gene therapy.

This study highlights the potential of selective organ targeting lipid nanoparticles in treating a range of genetic disorders. As research continues, the hope is that these innovations will lead to effective, long-term treatments for patients suffering from conditions like alpha-1 antitrypsin deficiency.